Publication | Closed Access

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats

InflammationMetabolic SyndromeDiabetes ManagementSglt2 InhibitorMedicinePhysiologyDiabetesVascular BiologyDiabetes ComplicationsDiabetic Microvascular ComplicationsDiabetes MellitusMicrovascular DysfunctionPharmacologyAtherosclerosisHealth Sciences